EC1 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States

To evaluate the cost-effectiveness of nivolumab plus ipilimumab plus two cycles of platinum doublet chemotherapy (NIVO+IPI+PDC) versus four cycles of PDC in the first-line (1L) treatment of stage IV or recurrent non-small cell lung cancer (NSCLC) from a health insurance perspective in the United States (US).

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Polyzoi, H. Sandhu, J. Maervoet, Y. Yuan, M. Chaudhary, N. Varol, A. Lee, P. Dale, C. Jones, S.J. Lubinga, J.R. Penrod Tags: Economic Evaluation in Oncology Studies Source Type: research